Valeo Pharma Inc. VPHIF
Set alert
At close · Oct 30
- YTD
- 0.00%
- 1 year
- -66.67%
- Open
- 0.1181
- Prev close
- 0.0001
- Mkt cap
- 9.87K
- Vol
- 4.50K
- Avg vol
- 0
- EPS
- -0.27
- P/E
- 0.00
More statistics
- Low
- 0.1181
- High
- 0.1181
News
2 years ago proactiveinvestors.com
Valeo Pharma adds chief development officer to drive growth initiatives
Valeo Pharma Inc. (TSX:VPH, OTCQB:VPHIF) announced that Al Moghaddam will be taking up the newly created role of chief development officer and, as a result will be stepping down from the company's…
2 years ago proactiveinvestors.com
Valeo Pharma sees record 2Q revenue boosted by respiratory products and core brand growth
Valeo Pharma Inc. (TSX:VPH, OTCQB:VPHIF) saw revenue for the second quarter of 2024 increase primarily driven by successful promotional activities for respiratory products, increased sales of…
2 years ago proactiveinvestors.com
Valeo Pharma restructures field operations to save over $5m annually
Valeo Pharma Inc said it has launched a restructuring of its field sales operations, taking cost-cutting to more than $7 million a year, including other recent measures. The latest initiative, which…
2 years ago proactiveinvestors.com
Valeo Pharma taps life sciences leader for board position
Valeo Pharma Inc. (TSX:VPH, OTCQB:VPHIF) has announced the appointment of Al Moghaddam to its board of directors. The Kirkland, Quebec-based pharmaceutical company highlighted that Moghaddam brings…
2 years ago proactiveinvestors.com
Valeo Pharma sees 1Q revenue increase on strong performance from respiratory division
Canadian pharmaceutical company Valeo Pharma Inc. (TSX:VPH, OTCQB:VPHIF) reported a 3% increase in first quarter revenue compared to the same period in the previous year driven by strong sales from…
2 years ago proactiveinvestors.com
Valeo Pharma unveils boardroom reshuffle
Valeo Pharma Inc. (TSX:VPH, OTCQB:VPHIF) announced a boardroom reshuffle that includes the addition of two new members and the departure of four. Robert Raich and Charles Bisaillon have joined as…
2 years ago proactiveinvestors.com
Valeo Pharma amends Novartis eye treatment distribution agreement
Valeo Pharma Inc. (TSX:VPH, OTCQB:VPHIF) has unveiled changes to a seven-year agreement with Novartis Pharmaceuticals for the distribution of its eye treatment. Xiidra, a treatment for dry eye, will…
2 years ago proactiveinvestors.com
Valeo Pharma achieves record revenues for fiscal 2023
Valeo Pharma Inc. (TSX:VPH, OTCQB:VPHIF) has reported record revenues of $54 million for fiscal 2023, representing a 94% year-over-year increase driven by increased demand for its prescription…
2 years ago proactiveinvestors.com
Valeo Pharma announces cost-reduction initiatives as it welcomes new CFO
Valeo Pharma Inc. (TSX:VPH, OTCQB:VPHIF) told investors it expects to cut its operating expenses by more than $2 million a year by streamlining its organizational structure and commercial support…
2 years ago proactiveinvestors.com
Valeo Pharma welcomes Richard Lajoie to board of directors
Valeo Pharma Inc. (TSX:VPH, OTCQB:VPHIF) said Richard Lajoie has joined its board of directors while Maureen C. Brennan has retired from the board.
3 years ago proactiveinvestors.com
Valeo Pharma CEO credits Enerzair for strong position on Canada's top-growing companies list
Valeo Pharma Inc. (TSX:VPH, OTCQB:VPHIF) CEO Steve Saviuk joined Proactive's Stephen Gunnion to discuss the company's strong position on the Globe and Mail's Report on Business annual list of…
3 years ago proactiveinvestors.com
Valeo Pharma secures spot on Canada's top-growing companies list
Valeo Pharma Inc. (TSX:VPH, OTCQB:VPHIF) highlighted to investors that it has placed at spot 151 on the Globe and Mail's Report on Business annual list of Canada's top-growing companies. The company…
3 years ago proactiveinvestors.com
Valeo Pharma secures $5M credit facility agreement with Accord Financial
Valeo Pharma Inc. (TSX:VPH, OTCQB:VPHIF) told investors it has entered into a $5 million credit facility with Accord Financial (TSX:ACD) which it said provides it with additional financial liquidity…
3 years ago proactiveinvestors.com
Valeo Pharma reports record quarterly revenue or strong demand for Enerzair and Atectura therapies
Valeo Pharma Inc. (TSX:VPH, OTCQB:VPHIF) has reported its seventh consecutive rise in revenues to a quarterly record due to strong growth in its Enerzair and Atectura asthma therapies. The Canadian…
3 years ago proactiveinvestors.com
Valeo Pharma raises funds totalling $4.5M
Valeo Pharma Inc. (TSX:VPH, OTCQB:VPHIF) has closed a non-brokered private placement offering, raising gross proceeds of $3.92 million. The company also secured a loan agreement with a related party…
3 years ago proactiveinvestors.com
Valeo Pharma bolsters board with two new directors
Valeo Pharma Inc. (TSX:VPH, OTCQB:VPHIF) said Tamara Close and Didier Leconte have both joined its board of directors, noting that following the appointments, Valeo's board now comprises of eight…
3 years ago proactiveinvestors.com
Valeo Pharma reports record quarterly revenues
Valeo Pharma Inc. (TSX:VPH, OTCQB:VPHIF) has reported record quarterly revenues of $13.6 million for its second quarter ending April 30, 2023, representing a substantial increase of 184% compared to…
3 years ago proactiveinvestors.com
Valeo Pharma expects 2Q revenues to set quarterly record
Valeo Pharma Inc. (TSX:VPH, OTCQB:VPHIF) said it expects revenues in the second quarter to exceed $13.5 million, a quarterly record, with operating expenses seen remaining in line with previous…
3 years ago proactiveinvestors.com
Valeo Pharma reports record 1Q revenue and gross profit buoyed by new products and higher market share
Valeo Pharma Inc. (TSX:VPH, OTCQB:VPHIF) said its revenue for the first quarter ended January 31, 2023, rose by 210% to a record $13.2 million, up from $4.2 million in the corresponding period of…
3 years ago proactiveinvestors.com
Valeo Pharma obtains public reimbursement for Onstryv in Quebec expanding access to the drug for Parkinson's patients
Valeo Pharma Inc. (TSX:VPH, OTCQB:VPHIF) said Onstryv (safinamide) for the treatment of patients with Parkinson's disease is now listed for reimbursement on the Public Prescription Drug Insurance…